Physician profile
Leandro Antonio Mena
NPI 1497718027
$140,884.02
in general payments reported to CMS, 2019-2025
14 companies · $18K in 2025
The $18K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $18K · 2021: $13K · 2024: $6,688 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $3,379 · Honoraria: $1,608 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,578.36 |
| Travel and Lodging | $3,379.44 |
| Honoraria | $1,608.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Food and Beverage | $289.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58,266.66 | 2019-2025 | |
| Viiv Healthcare Company | $52,201.16 | 2019-2021 | |
| Abbott Laboratories | $14,276.68 | 2024-2025 | Alere Binaxnow Influenza A & B Card 2 |
| Merck Sharp & Dohme LLC | $9,745.34 | 2019-2021 | |
| Roche Molecular Systems, INC. | $2,400.00 | 2019 | |
| La Jolla Pharmaceutical Company | $1,769.20 | 2024 | |
| Glaxosmithkline, LLC. | $1,108.66 | 2019 | |
| Orasure Technologies INC. | $1,000.00 | 2024 | Inteliswab |
| Janssen Products, Lp | $99.95 | 2021 | |
| Theratechnologies INC. | $16.37 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandro Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.